Neurology

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2...

Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression...

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing...

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured...

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company...

CND Life Sciences to Highlight Momentum of Skin Biopsy Diagnostic Tool for Parkinson’s Disease and Related Disorders at the American Academy of Neurology 2024 Annual Meeting

Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC),...

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population...

Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024

HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused,...

error: Content is protected !!